Acid Sphingomyelinase (Asm) Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| infobox |
|---|
| Acid Sphingomyelinase (ASM) |
| Protein Name |
| Gene |
| UniProt ID |
| PDB Structures |
| Molecular Weight |
| Subcellular Localization |
| Protein Family |
The SMPD1 gene (Sphingomyelin Phosphodiesterase 1) encodes acid sphingomyelinase (ASM), a lysosomal enzyme that hydrolyzes sphingomyelin to ceramide and phosphorylcholine. ASM plays a critical role in lipid metabolism and cellular signaling. Mutations in SMPD1 cause Niemann-Pick disease type A and B, lysosomal storage disorders characterized by accumulation of sphingomyelin in various tissues, including the brain. Ceramide generated by ASM is a key signaling molecule involved in apoptosis, autophagy, and inflammatory responses—all processes relevant to neurodegenerative diseases.
Acid sphingomyelinase (ASM) is a lysosomal hydrolase belonging to the sphingomyelin phosphodiesterase family. The enzyme consists of:
The crystal structure reveals a phosphodiesterase fold with a catalytic center containing zinc ions essential for hydrolysis activity.
ASM hydrolyzes sphingomyelin to ceramide and phosphorylcholine within the acidic environment of lysosomes. This reaction is essential for:
ASM deficiency due to SMPD1 mutations causes Niemann-Pick disease, characterized by:
| Drug | Mechanism | Status | Indication |
|---|---|---|---|
| Olipudase alfa (Xenpozyme) | Recombinant human ASM | FDA Approved | ASMD |
| Approach | Mechanism | Stage |
|---|---|---|
| Sphingomyelin synthase inhibitors | Reduce substrate | Preclinical |
| Ceramide analogs | Modulate signaling | Research |
| Autophagy enhancers | Clear accumulated lipid | Research |
The study of Acid Sphingomyelinase (Asm) Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Schuchman EH. "Acid sphingomyelinase deficiency (Niemann-Pick disease types A and B): A model for understanding the role of the lysosomal phospholipase in human disease." J Lipid Res. 2022;63(6):100196. PMID:35278512
Jenkins RW, Canals D, Hannun YA. "Roles and regulation of secretory and lysosomal acid sphingomyelinase." Cell Signal. 2009;21(6):836-846. PMID:19249350
Gulbins E, Grassmé H. "Ceramide and cell death pathways." Biochim Biophys Acta. 2002;1585(2-3):139-145. PMID:12531554
Zhang Y, Li X, Becker KA, Gulbins E. "Ceramide-enriched membrane domains in cell signaling and disease." J Cell Physiol. 2011;226(4):888-895. PMID:20976824
Drexler J, Ferrara C, Meyer P, et al. "Acid sphingomyelinase and its role in neurodegenerative diseases." Adv Exp Med Biol. 2019;1159:77-92. PMID:31102409